2.66  -0.01 (-0.37%)		08-17 16:00
Open: 2.64 High: 2.74 Volume: 412,838		Pre. Close: 2.67 Low: 2.62 Market Cap: 192(M)

Short term
Mid term
Targets	6-month :	3.21	1-year :	3.75
Resists	First :	2.75	Second :	3.21
Pivot price	2.36
Supports	First :	2.34	Second :	2.08
MAs	MA(5) :	2.57	MA(20) :	2.31
	MA(100) :	2.44	MA(250) :	2.22
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	93	D(3) :	91.1
RSI	RSI(14): 67.1
52-week	High :	3.59	Low :	1.21

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ ABOS ] has closed below upper band by 6.1%. Bollinger Bands are 13.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	2.69 - 2.7	2.7 - 2.71
Low:	2.43 - 2.44	2.44 - 2.45
Close:	2.65 - 2.67	2.67 - 2.68

Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.

Sat, 15 Aug 2026
Acumen Pharmaceuticals Inc (ABOS) Stock News Today - TradingKey

Wed, 12 Aug 2026
ABOS: Net loss narrowed and cash runway extends into early 2027, but going concern risk persists - TradingView

Wed, 12 Aug 2026
Acumen Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:ABOS) 2026-08-12 - Seeking Alpha

Wed, 12 Aug 2026
Acumen Pharmaceuticals Reports Second-Quarter 2026 Results and Advances Alzheimer’s Pipeline, with ALTITUDE-AD Topline Data Expected in Late 2026 - Quiver Quantitative

Wed, 05 Aug 2026
Alzheimer’s drug developer Acumen sets Aug. 12 webcast at 8 a.m. - Stock Titan

Wed, 05 Aug 2026
Price to book forward of Acumen Pharmaceuticals, Inc. – NASDAQ:ABOS - TradingView

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	72 (M)
Shares Float	37 (M)
Held by Insiders	6.8 (%)
Held by Institutions	67.8 (%)
Shares Short	2,810 (K)
Shares Short P.Month	1,890 (K)

EPS	-1.86
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.21
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-42.4 %
Return on Equity (ttm)	-93.3 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	-1.46
Sales Per Share	0
EBITDA (p.s.)	-1.59
Qtrly Earnings Growth	0 %
Operating Cash Flow	-106 (M)
Levered Free Cash Flow	-67 (M)

PE Ratio	-1.45
PEG Ratio	0
Price to Book value	2.21
Price to Sales	0
Price to Cash Flow	-1.84

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.